– USA, NJ – Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announced the appointments of Keith Murphy and Edward Neugeboren to its Board as independent Directors, effective March 11, 2025.
In addition, Dr. Matt Wikler and Natasha Giordano stepped down from the Board.
“We are thrilled to announce the addition of Keith and Edward to our Board,” said CEO Jerome Jabbour. “Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continuing our work to create long-term value for shareholders.”
Keith Murphy will become Chair of the Nominating and Governance Committee, and serve on the Compensation Committee, while Edward Neugeboren will become Chair of the Compensation Committee and a member of the Audit Committee.
About Keith Murphy
Keith Murphy is currently a Director and Executive Chairman of Organovo Holdings, Inc. (Nasdaq: ONVO) and CEO and Chairman of Viscient Bio, Inc. Before co-founding Viscient Bio in 2017, he founded Organovo in 2007 and led all company operations until 2017. He co-invented the NovoGen MMX bioprinter platform and grew Organovo through early investments and pharma corporate partnerships. Before Organovo, Keith Murphy spent ten years at Amgen in roles of increasing responsibility, including four years as the Global Operations Leader of denosumab, now marketed as Prolia & Xgeva ($6B+ annual sales). Before Amgen, he played a key role at Alkermes in the successful development of once-monthly human growth hormone (hGH) in partnership with Genentech.
Keith Murphy holds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology (MIT) and is an alumnus of the UCLA Anderson School of Management. He serves as co-chair of the Board of No Patient Left Behind and on the Board of Directors of California Life Sciences, the state’s life science industry public policy, advocacy, and business leadership organization.
About Edward Neugeboren
Edward Neugeboren has over thirty-three years of diversified healthcare experience in pharmaceutical operations, business development, corporate management, corporate governance, investment banking, asset management, and institutional equity research. He serves on the Board of Directors of Grace Therapeutics, Inc. (Nasdaq: GRCE), a late-stage biopharmaceutical company addressing rare and orphan diseases, where he is a member of the Audit, Compensation, and Nominating & Governance Committees.
Since January of 2016, Edward Neugeboren has served as CSO of Cronus Pharma, LLC, a fully integrated R&D, manufacture, ng and sales & marketing animal health pharmaceutical company. Edward Neugeboren leads Cronus Pharma’s commercial operations, sales and marketing, strategic planning, business development, and M&A and is also responsible for developing and executing overall corporate strategy as well as corporate and portfolio acquisitions and licensing.
Edward Neugeboren was CSO for the parent pharmaceutical group comprised of Rising Pharma Holdings, Inc., a generic pharmaceutical company, and Casper Pharma, LLC, a specialty pharmaceutical company. Additionally, he is the Founder and Managing Partner of QuadView Healthcare Advisors, a healthcare investment banking and business development firm. Mr. Neugeboren was previously a Managing Director of Third Ridge Capital Management, LLC, a U.S. equity hedge fund.
Edward Neugeboren was also CAO and Director of Equity Research Operations at Lehman Brothers, where he was a senior member of the management team responsible for operations for a 200-person department with direct management of technology, finance, editorial and production, human resources, and compliance. He was Deputy Director of Equity Research at UBS, formerly Warburg Dillon Read, and Director of Equity Research Operations responsible for operations for a 150-person department. Additionally, he participated on the Investment Policy & Equity Commitment Committees.
Edward Neugeboren began his career in 1992 as an equity research analyst covering the Specialty Pharmaceuticals industry, including Generic Drugs and Drug Delivery at Dillon, Read & Co., Kidder, Peabody & Co., and Furman, Selz, Inc. He was a member of the top-ranked Greenwich Associates Mid-Cap Pharmaceuticals Team. He also served as an Advisor to Healthcare Capital Corp., Inc., and its merger with AlphaTau, Inc., a radiopharmaceutical company; Director of Elite Pharmaceuticals Inc., a public specialty pharmaceutical company; and KineMed, Inc., a private biopharmaceutical company.
Edward Neugeboren graduated with a BA in Economics from Union College.
About Matinas BioPharma
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology.
For more: https://www.matinasbiopharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.